Catalina Capital Group’s Bristol-Myers Squibb BMY Stock Holding History

Catalina Capital Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,970	Closed	-$225K	–	211
2024 Q4	$225K	Buy	+3,970	New	+$222K	0.07%	274

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Catalina Capital Group's BMY Position: Q1 2025 in Review

Catalina Capital Group sold out of Bristol-Myers Squibb (BMY) in Q1 2025, closing a stake of 3,970 shares — an estimated $225K sold.

Catalina Capital Group first reported a position in BMY in Q4 2024 and held it in 1 quarter. The position peaked at $225K in Q4 2024. 2,478 funds tracked by Wall St. Rank hold BMY as of Q1 2025.

Catalina Capital Group reported no remaining Bristol-Myers Squibb position as of Q1 2025 after selling out during the quarter.
Catalina Capital Group sold 3,970 Bristol-Myers Squibb shares in Q1 2025, an estimated $225K.
Catalina Capital Group first reported a position in Bristol-Myers Squibb in Q4 2024 and held it in 1 quarter.
Catalina Capital Group's Bristol-Myers Squibb position peaked at $225K in Q4 2024.
2,478 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2025.

Based on Catalina Capital Group's 13F filing for Q1 2025, filed 21 Apr 2025.